Artemis Pharmaceuticals and Acceleron Pharma Cooperate in Mouse Genetics
COLOGNE, Germany, August 26 /PRNewswire/ -- Artemis Pharmaceuticals GmbH,
Cologne, and Acceleron Pharma, Inc., Cambridge, Mass., USA., have signed a
cooperation agreement in mouse genetics. As part of this cooperation, Artemis
will apply its unique ArteMice(TM) technology platforms to generate a
specifically genetically engineered mouse model system for Acceleron.
ArteMice(TM) CONDITIONAL gene targeting and ArteMice(TM) SPEED
technologies allow the rapid and highly efficient generation of complex
genetically modified mouse lines. These are used as highly relevant model
systems in drug discovery research and functional target validation to
identify genes that play a central role in disease processes and disease
therapy. Acceleron will use the mouse model to develop drugs for the
treatment of musculoskeletal and metabolic disorders.
Financial details were not disclosed by the partners.
About Artemis:
Artemis Pharmaceuticals has developed an exceptionally efficient and
powerful technology basis for the identification and validation of disease
related genes. The ArteMice(TM) SPEED platform provides the company with a
leading technology position with regard to the efficient, rapid production of
complex genetically modified mouse models. ArteMice(TM) technology enables
the mouse gene to be completely replaced by its human orthologe. These
"humanized mice" can play a potentially important role in drug discovery by
providing an optimal model for the early in vivo testing of lead compound
toxicity and efficacy on the specific human target. When combined with shRNAi
the ArteMice(TM) technology provides a rapid and efficient way to knock down
gene expression in all tissues of the mouse in vivo. Artemis cooperates with
Merck,Inc.,Aventis, Bayer AG, Biovitrum AB, Evotec Neurosciences, Exelixis,
Regeneron, the German Cancer Research Center (DKFZ) and others. Artemis is a
wholly owned subsidiary of Exelixis Inc., South San Francisco, CA, USA
(Nasdaq:EXEL)
Website at artemispharma.de.
About Acceleron Pharma
Acceleron is a biopharmaceutical company developing drugs for important
unmet medical needs through proprietary approaches that exploit the
therapeutic potential of a large family of growth and differentiation
factors. Drug candidates will include both novel agonists and antagonists.
The company was founded in 2003 and builds upon important ongoing research in
the laboratories of its academic founders and consultants.
For further information please contact:
Artemis :
Artemis Pharnaceuticals GmbH
Monika Hahn
Tel: +49(0)221-96453-10
Mail : m.hahn@artemispharma.de
Acceleron:
Glenn Batchelder
Acceleron Pharma, Inc.
+1-617-576-2220 |
